Hospital and Clinics Provider's Orders	ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE Patient Identification			
Page 1 of 4 Patient identification ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.				
Weight:kg Height: Allergies: Diagnosis Code:				
Treatment Start Date: Patient to follow up with provider on date:				
 This plan will expire after 365 days at which time a new order will need to be placed GUIDELINES FOR ORDERING Send FACE SHEET and H&P or most recent chart note. Monitor drug levels and adjust dose as necessary. DAPTOmycin: draw Creatine Phosphokinase (CPK) - Plasma, Weekly. Monitor CPK more frequently in patients with recent prior or concomitant therapy with an HMG-CoA reductase 				
GUIDELINES FOR ORDERING 1. Send FACE SHEET and H&P or most r 2. Monitor drug levels and adjust dose as no	ecent chart note. ecessary.			

- b. Vancomycin: draw trough level just before the 4th dose and once weekly.
- c. Aminoglycosides: For daily dosing, draw random level 12 hours after the start of infusion and once weekly. For every 8-12 hour dosing, draw peak and trough weekly. Troughs are drawn just before the dose and peaks are drawn 30 minutes after the end of the dose.

NURSING ORDERS:

1. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

Aminoglycosides:

LABS:

- □ CBC with differential, every _____ (visit)(days)(weeks)(months) Circle One
 □ CMP, every _____ (visit)(days)(weeks)(months) Circle One
- □ Urine Dipstick w/o micro (10 dip), weekly during therapy
- Daily dosing

□ Random ______ level, 12 hours post-dose, weekly during therapy

- Traditional dosing
 - Peak _____ level, weekly during therapy
- □ Trough ______ level, weekly during therapy □ Labs already drawn. Date: ______

MEDICATION:

- amikacin _____ mg/kg = ____mg in sodium chloride 0.9% 100 mL IV, over 30-60 minutes
- gentamicin _____ mg/kg = ____ mg in sodium chloride 0.9% 100 mL IV, over 30-60 minutes
- □ tobramycin _____ mg/kg = ____ mg in sodium chloride 0.9% 100 mL IV, over 20-60 minutes

Interval: (must check one)

- □ Daily x ____ doses
- Every ____ days x ____ doses

ONLINE 02/2023 [supersedes 08/2021]

Oregon Health & Science University Hospital and Clinics Provider's Orders		
	ACCOUNT NO.	
OHSU ADULT AMBULATORY INFUSION ORDER	MED. REC. NO.	
Health Antibiotic Therapy	NAME	
(Aminoglycosides, Daptomycin, & Glycopeptides)	BIRTHDATE	
Page 2 of 4		
	Patient Identification	
ALL ORDERS MUST BE MARKED I	N INK WITH A CHECKMARK (✓) TO BE ACTIVE.	
DAPTOmycin:		
 CBC with differential, every (visit)(days)(weeks)(months) – Circle One CMP, every (visit)(days)(weeks)(months) – Circle One CK, PLASMA, ONCE prior to therapy CK, PLASMA, weekly during therapy Labs already drawn. Date: 		
MEDICATION:		

Interval: (must check one)

- □ ONCE
- Daily x _____ doses
- Every _____ days x _____ doses

Dalbavancin:

LABS:

- CBC with differential, every _____ (visit)(days)(weeks)(months) Circle One
- □ CMP, every _____(visit)(days)(weeks)(months) Circle One
- C-reactive protein, every (visit)(days)(weeks)(months) Circle One
- Labs already drawn. Date: _____

MEDICATION:

□ Single dose regimen

dalbavancin (DALVANCE) **1500 mg** in dextrose 5%, intravenous, ONCE, over 30 minutes **Interval:** ONCE

□ Two-dose regimen

dalbavancin (DALVANCE) **1000 mg** in dextrose 5%, intravenous, ONCE, over 30 minutes **Interval:** ONCE

&

dalbavancin (DALVANCE) **500 mg** in dextrose 5%, intravenous, ONCE, over 30 minutes **Interval:** ONCE, 7 days after initial dose

□ Other

dalbavancin (DALVANCE) _____ mg in dextrose 5%, intravenous, ONCE, over 30 minutes Interval: _____

Oregon Health & Science University Hospital and Clinics Provider's Orders

OHSU ADULT AMBULATORY INFUSION ORDER Health Antibiotic Therapy (Aminoglycosides, Daptomycin, & Glycopeptides) ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE

Page 3 of 4

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Vancomycin:

- LABS:
 - □ CBC with differential, every _____ (visit)(days)(weeks)(months) Circle One
 - □ CMP, every _____(visit)(days)(weeks)(months) Circle One
 - □ Vancomycin trough, weekly during therapy (first level prior to 4th dose)
 - Labs already drawn. Date: _____

MEDICATION:

- □ vancomycin 750 mg in sodium chloride 0.9% 150 mL IV
- □ vancomycin 1000 mg in sodium chloride 0.9% 250 mL IV
- □ vancomycin 1250 mg in sodium chloride 0.9% 250 mL IV
- □ vancomycin 1500 mg in sodium chloride 0.9% 300 mL IV
- □ vancomycin 25 mg/kg/day in sodium chloride 0.9% IV, ONCE over 24 hours, continuous infusion via CADD (OHSU only)
- □ vancomycin 30 mg/kg/day in sodium chloride 0.9% IV, ONCE over 24 hours, continuous infusion via CADD (OHSU only)

Infuse doses up to 1000 mg over at least 60 minutes and doses greater than 1000 mg over 120 minutes. Infusion rate not to exceed 17 mg/min

Interval: (must check one)

□ ONCE

□ Daily x ____ doses

□ Every ____ days x ____ doses

FOR InfuSystem[™] AMBULATORY PUMP USE (OHSU only; hook up at infusion location):

Duration:

□ ____ days

HYPERSENSITIVITY MEDICATIONS:

- NURSING COMMUNICATION If hypersensitivity or infusion reactions develop, temporarily hold the infusion and notify provider immediately. Administer emergency medications per the Treatment Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for symptom monitoring and continuously assess as grade of severity may progress.
- 2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 3. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

Oregon Health & Science University Hospital and Clinics Provider's Orders OHSU Health ADULT AMBULATORY INFUSION ORDER Antibiotic Therapy (Aminoglycosides, Daptomycin, & Glycopeptides)	ACCOUNT NO. MED. REC. NO. NAME BIRTHDATE	
Page 4 of 4	Patient Identification	
ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.		

By signing below, I represent the following:

I am responsible for the care of the patient (*who is identified at the top of this form*); I hold an active, unrestricted license to practice medicine in: *Oregon* (*check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon*);

My physician license Number is # _______(MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

Provider signature:	Date/Time:	
Printed Name:	Phone:	Fax:

Central Intake:

Phone: 971-262-9645 (providers only) Fax: 503-346-8058

Please check the appropriate box for the patient's preferred clinic location:

- Beaverton
 OHSU Knight Cancer Institute
 15700 SW Greystone Court
 Beaverton, OR 97006
 Phone number: 971-262-9000
 Fax number: 503-346-8058
- □ Gresham Legacy Mount Hood campus Medical Office Building 3, Suite 140 24988 SE Stark Gresham, OR 97030 Phone number: 971-262-9500 Fax number: 503-346-8058

□ NW Portland

Legacy Good Samaritan campus Medical Office Building 3, Suite 150 1130 NW 22nd Ave Portland, OR 97210 Phone number: 971-262-9600 Fax number: 503-346-8058

□ Tualatin

Legacy Meridian Park campus Medical Office Building 2, Suite 140 19260 SW 65th Ave Tualatin, OR 97062 Phone number: 971-262-9700 Fax number: 503-346-8058

Infusion orders located at: www.ohsuknight.com/infusionorders